Preparing your space
Your library and workspace are being arranged now.
Preparing your space
Your library and workspace are being arranged now.
Financial data on TradingView ↗Reported statements, ratios and ownership, alongside this research.
Philip Morris International sells cigarettes and smoke-free nicotine products (IQOS heated tobacco, ZYN pouches, VEEV e-vapor) to adult consumers in roughly 170 cigarette and 106 smoke-free markets. [S1]
Revenue comes from selling consumable nicotine products at premium prices. In FY2025, smoke-free products generated $16.9bn (41.5% of revenue) and combustibles $23.8bn. Pricing adds 6-9% annually; smoke-free volumes grow 8-15%; cigarette volumes decline 2-3%. [S1][S2]
Explore the research to see how business evidence informs assumptions and valuation.
Start with the business evidence, then follow the assumptions through to scenarios and valuation.
Financial data on TradingView ↗Reported statements, ratios and ownership, alongside this research.
Valuation and assumptionsPMI's smoke-free transition is working, but the stock trades at 23x forward earnings, pricing in continued high-single-digit volume growth and stable regulation. The tension is whether smoke-free growth can remain strong enough to justify the premium while regulatory and competitive risks build.
A valuation model that works backward from a share price to find combinations of growth, margins, and other assumptions consistent with that price.
In this report: Used in section 22 to back out the revenue growth and margin assumptions embedded in the $191.06 share price.
Regulatory crackdown on smoke-free products. If the FDA revokes IQOS or ZYN authorisations, or major markets impose punitive taxes or flavour bans, PMI's growth engine stalls and intrinsic value falls materially.
The risk that government action (FDA authorisations, excise taxes, flavour bans, marketing restrictions) alters the economics of nicotine products. It is the widest uncertainty in PMI's valuation because it is both unpredictable and high-impact.
In this report: A severe regulatory crackdown on smoke-free products could permanently reduce PMI's intrinsic value by 15-20% or more.
PMI sells cigarettes and smoke-free nicotine products (IQOS heated tobacco, ZYN pouches, VEEV e-vapor) to adult consumers in roughly 170 cigarette and 106 smoke-free markets. FY2025 revenue was $40.65bn, with smoke-free products at $16.9bn (41.5% of revenue) and combustibles at $23.8bn. Pricing adds 6-9% annually, smoke-free volumes grow 8-15%, and cigarette volumes decline 2-3%. Operating margin was 36.6% in FY2025 and is expanding as smoke-free mix rises.
The sensitivity of operating profit to changes in revenue when some operating costs are fixed.
In this report: Smoke-free products carry higher gross margins; as their revenue share rises, operating margin expands faster than revenue, which is central to the base case.
The shift in PMI's revenue mix from combustible cigarettes to heated tobacco (IQOS), oral nicotine pouches (ZYN), and e-vapor (VEEV). Smoke-free products have higher gross margins, faster volume growth, and different regulatory treatment than cigarettes.
In this report: It is the single biggest driver of PMI's revenue growth, margin expansion, and terminal value. If it stalls, the base case breaks.
At $191.06 with 1,560M diluted shares, market cap is roughly $298bn and enterprise value roughly $338bn. A reverse DCF at a 5.9% WACC and 2.5% terminal growth implies 6-7% revenue growth, 39-40% operating margin, and 9-11% EPS growth for a decade. This matches management guidance and historical performance, so the stock is fairly valued, not cheap.
A valuation model that works backward from a share price to find combinations of growth, margins, and other assumptions consistent with that price.
In this report: Used in section 22 to back out the revenue growth and margin assumptions embedded in the $191.06 share price.
The weighted average required return of a company's debt and equity providers, used to discount cash flows to the firm.
In this report: The discount rate used to present-value PMI's free cash flows; a 5.9% WACC is estimated from a low beta and investment-grade debt cost.
I hold PMI. The business is high quality with a wide moat and strong cash generation, but the expected return of roughly 12-13% annually in the base case does not leave a margin of safety at $191. My base-case intrinsic value is $195, the bear case is $135, and the bull case is $260. The risk/reward is balanced.
NOPAT divided by invested capital. It measures how efficiently a company turns capital into operating profit. A ROIC well above WACC indicates economic profit and value creation.
In this report: PMI's FY2025 ROIC was approximately 34.5%, far above its 5.9% WACC, confirming that growth is value-creating rather than merely increasing size.
Smoke-free volume growth (currently 8%) is the primary driver. A 500bps change moves intrinsic value by roughly $4.50 per share.
The shift in PMI's revenue mix from combustible cigarettes to heated tobacco (IQOS), oral nicotine pouches (ZYN), and e-vapor (VEEV). Smoke-free products have higher gross margins, faster volume growth, and different regulatory treatment than cigarettes.
In this report: It is the single biggest driver of PMI's revenue growth, margin expansion, and terminal value. If it stalls, the base case breaks.
Combustible pricing power (currently 6-9%) drives revenue. A 200bps change moves intrinsic value by roughly $2.80 per share.
The ability to raise prices above cost inflation without losing enough volume to offset the revenue gain. In tobacco, it reflects brand loyalty, inelastic demand, and the fact that excise taxes are embedded in retail prices.
In this report: Combustible pricing power contributes 6-9% to annual revenue growth and offsets cigarette volume declines. It is a primary driver of intrinsic value.
Regulatory environment for smoke-free is the widest uncertainty. A severe crackdown could reduce intrinsic value by 15-20%.
The risk that government action (FDA authorisations, excise taxes, flavour bans, marketing restrictions) alters the economics of nicotine products. It is the widest uncertainty in PMI's valuation because it is both unpredictable and high-impact.
In this report: A severe regulatory crackdown on smoke-free products could permanently reduce PMI's intrinsic value by 15-20% or more.
Regulatory crackdown and competitive share loss slow smoke-free growth to 3-5%, revenue growth to 3-4%, and EPS growth to 4-5%. Multiple compresses to 15-16x, giving $135 per share.
The risk that government action (FDA authorisations, excise taxes, flavour bans, marketing restrictions) alters the economics of nicotine products. It is the widest uncertainty in PMI's valuation because it is both unpredictable and high-impact.
In this report: A severe regulatory crackdown on smoke-free products could permanently reduce PMI's intrinsic value by 15-20% or more.
Strategy continues. Smoke-free volumes grow 8-12%, pricing adds 6-8%, regulatory environment is stable, and EPS grows 9-11%. Multiple holds at 20x, giving $195 per share.
The shift in PMI's revenue mix from combustible cigarettes to heated tobacco (IQOS), oral nicotine pouches (ZYN), and e-vapor (VEEV). Smoke-free products have higher gross margins, faster volume growth, and different regulatory treatment than cigarettes.
In this report: It is the single biggest driver of PMI's revenue growth, margin expansion, and terminal value. If it stalls, the base case breaks.
Smoke-free adoption accelerates, IQOS U.S. exceeds expectations, and margins expand faster. EPS grows 13-15%, multiple expands to 22-24x, giving $260 per share.
The sensitivity of operating profit to changes in revenue when some operating costs are fixed.
In this report: Smoke-free products carry higher gross margins; as their revenue share rises, operating margin expands faster than revenue, which is central to the base case.
Quarterly smoke-free volume growth. Above 8% supports the thesis; below 5% for two quarters weakens it.
The shift in PMI's revenue mix from combustible cigarettes to heated tobacco (IQOS), oral nicotine pouches (ZYN), and e-vapor (VEEV). Smoke-free products have higher gross margins, faster volume growth, and different regulatory treatment than cigarettes.
In this report: It is the single biggest driver of PMI's revenue growth, margin expansion, and terminal value. If it stalls, the base case breaks.
ZYN U.S. shipment growth. Above 10% supports; below 5% for two quarters weakens.
FDA regulatory decisions on IQOS and ZYN authorisations. Revocation would break the thesis.
The risk that government action (FDA authorisations, excise taxes, flavour bans, marketing restrictions) alters the economics of nicotine products. It is the widest uncertainty in PMI's valuation because it is both unpredictable and high-impact.
In this report: A severe regulatory crackdown on smoke-free products could permanently reduce PMI's intrinsic value by 15-20% or more.
Stock-based compensation was not stored in the platform's XBRL tables and is reconstructed from the 10-K and secondary sources; the exact figure is approximate. Full proxy statement data on executive compensation was not available, so compensation figures come from secondary sources. The precise probability and timing of future regulatory actions cannot be established from available evidence. Litigation outcomes, including the Canadian settlement, are uncertain.
These model scenarios depend on their inputs. Review the assumptions and supporting evidence alongside the implied values.
earnings multiple v2 · as of 2026-10-25
Sign in for the price chart, where every input traces back to a filing, an adjustable scenario sandbox, and companies that move with PM.
Create a free account →